Nucleic acid based tetrahedral framework DNA nanostructures for fibrotic diseases therapy
Source abstract
Abstract
Abstract As a type of novel biomaterial, DNA nanomaterial has been widely applied to biomedical area due to its self-assembly properties. Meanwhile, fibrotic diseases are common health problems, which can lead to multiple organs dysfunction and even death if without proper intervention and treatment. Therefore, we aim to develop the nucleic acids based tetrahedral framework DNA nanostructures (TFNAs) for the treatment of fibrotic diseases. Four single-strand DNA were self-assembled to form tetrahedral framework DNA nanostructures and the anti-fibrotic effects of TFNAs were investigated with an in vitro TGF-β1-induced fibrotic model. TFNAs were successfully assembled and showed obvious cellular uptake. After TFNAs treatment, ROS overproduction, fibrosis-related biomolecules expression including collagen I, fibronectin and α-SMA were obviously reduced. DNA-based TFNAs could be promising biomaterials for the treatment of fibrotic diseases.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (74)
Show source-provided references
1. Programmable and multifunctional dna-based materials for biomedical applications
2. Multifunctional DNA nanomaterials for biomedical applications10.1155/2015/765492 ↗
3. Rapid chiral assembly of rigid DNA building blocks for molecular nanofabrication10.1126/science.1120367 ↗
4. A DNA nanostructure-based biomolecular probe carrier platform for electrochemical biosensing10.1002/adma.201002767 ↗
5. Advances in biological applications of self-assembled DNA tetrahedral nanostructures10.1016/j.mattod.2018.08.002 ↗
6. Self-assembled mirror DNA nanostructures for tumor-specific delivery of anticancer drugs10.1016/j.jconrel.2016.10.015 ↗
7. Tetrahedral framework nucleic acids promote corneal epithelial wound healing in vitro and in vivo
8. Cardioprotection of tetrahedral DNA nanostructures in myocardial ischemia-reperfusion injury10.1021/acsami.9b10645 ↗
9. Tetrahedral DNA nanostructures facilitate neural stem cell migration via activating RHOA/ROCK2 signalling pathway10.1111/cpr.12503 ↗
10. PEGylated protamine-based adsorbing improves the biological properties and stability of tetrahedral framework nucleic acids10.1021/acsami.9b09243 ↗
11. Neuroprotective and neurotherapeutic effects of tetrahedral framework nucleic acids on parkinson's disease in vitro10.1021/acsami.9b10308 ↗
12. Enhanced neural regeneration with a concomitant treatment of framework nucleic acid and stem cells in spinal cord injury10.1021/acsami.9b19079 ↗
13. Tetrahedral framework nucleic acids prevent retina ischemia-reperfusion injury from oxidative stress via activating the Akt/Nrf2 pathway10.1039/C9NR07171G ↗
14. Anti-inflammatory and Antioxidative Effects of Tetrahedral DNA Nanostructures via the Modulation of Macrophage Responses10.1021/acsami.7b17928 ↗
15. The clearance effect of tetrahedral DNA nanostructures on senescent human dermal fibroblasts10.1021/acsami.8b20530 ↗
16. DNA-based nanomedicine with targeting and enhancement of therapeutic efficacy of breast cancer cells10.1021/acsami.9b03449 ↗
17. Tetrahedral DNA nanostructure-delivered dnazyme for gene silencing to suppress cell growth10.1021/acsami.8b22444 ↗
18. Aptamer-targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7-positive tumours10.1111/cpr.12511 ↗
19. Enhanced efficacy of temozolomide loaded by a tetrahedral framework DNA Nanoparticle in the therapy for glioblastoma10.1021/acsami.9b13829 ↗
20. An Intelligent DNA nanorobot with in vitro enhanced protein lysosomal degradation of HER210.1021/acs.nanolett.9b01320 ↗
21. Inhibiting methicillin-resistant Staphylococcus aureus by tetrahedral DNA nanostructure-enabled antisense peptide nucleic acid delivery10.1021/acs.nanolett.8b02166 ↗
22. Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: decisive role of Bax, Nrf2, NF-kappaB, Muc5ac, TNF-alpha and IL-1beta10.1016/j.cbi.2015.06.019 ↗
23. From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities10.1007/s11897-017-0343-y ↗
24. Mechanistic connection between inflammation and fibrosis10.1038/ki.2010.418 ↗
25. Inflammatory processes in renal fibrosis10.1038/nrneph.2014.114 ↗
26. Human Fibrotic Diseases: current challenges in fibrosis research10.1007/978-1-4939-7113-8_1 ↗
27. Liver fibrosis and repair: immune regulation of wound healing in a solid organ10.1038/nri3623 ↗
28. Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities10.1016/S2213-2600(16)30222-3 ↗
29. Kidney Fibrosis: origins and interventions10.1097/TP.0000000000001608 ↗
30. BAMBI inhibits skin fibrosis in keloid through suppressing TGF-beta1-induced hypernomic fibroblast cell proliferation and excessive accumulation of collagen I
31. Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis10.1053/j.gastro.2015.09.040 ↗
32. Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions10.1016/j.phrs.2015.04.012 ↗
33. Silicosis in the form of progressive massive fibrosis: a diagnostic challenge10.4103/0019-5278.197548 ↗
34. MicroRNA-21 in skin fibrosis: potential for diagnosis and treatment10.1007/s40291-017-0294-8 ↗
35. Neupogen and mesenchymal stem cells are the novel therapeutic agents in regeneration of induced endometrial fibrosis in experimental rats
36. Cellular and molecular mechanisms of fibrosis10.1002/path.2277 ↗
37. Fibrosis: targeting EMT to reverse renal fibrosis10.1038/nrneph.2015.133 ↗
38. Pathogenesis of Type 2 Epithelial to Mesenchymal Transition (EMT) in renal and hepatic fibrosis10.3390/jcm5010004 ↗
39. Extracellular matrix: preconditioning the ECM for fibrosis10.1038/nrm3906 ↗
40. Mechanisms of fibrosis: therapeutic translation for fibrotic disease10.1038/nm.2807 ↗
41. Fibrosis–a common pathway to organ injury and failure10.1056/NEJMra1300575 ↗
42. Therapy for fibrotic diseases: nearing the starting line10.1126/scitranslmed.3004700 ↗
43. Novel anti-fibrotic therapies10.3389/fphar.2017.00318 ↗
44. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis10.1080/14728214.2018.1471465 ↗
45. Mechanisms of alveolar epithelial injury, repair, and fibrosis10.1513/AnnalsATS.201410-448MG ↗
46. Role of endoplasmic reticulum stress in epithelial-mesenchymal transition of alveolar epithelial cells: effects of misfolded surfactant protein10.1165/rcmb.2010-0347OC ↗
47. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis10.1016/S0002-9440(10)62351-6 ↗
48. Nrf2 antioxidant pathway suppresses Numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis10.1038/s41419-017-0198-x ↗
49. Effect of tetrahedral DNA nanostructures on proliferation and osteo/odontogenic differentiation of dental pulp stem cells via activation of the notch signaling pathway10.1016/j.nano.2018.02.004 ↗
50. Neuroprotective Effect of Tetrahedral DNA Nanostructures in a Cell Model of Alzheimer's Disease10.1021/acsami.8b07827 ↗
51. Self-assembly of DNA-based drug delivery nanocarriers with rolling circle amplification10.1016/j.ymeth.2013.05.024 ↗
52. Single-particle tracking and modulation of cell entry pathways of a tetrahedral DNA nanostructure in live cells10.1002/anie.201403236 ↗
53. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery10.1038/nnano.2012.73 ↗
54. Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression10.1002/emmm.200900043 ↗
55. Reducing protein oxidation reverses lung fibrosis10.1038/s41591-018-0090-y ↗
56. Oxidative stress and pulmonary fibrosis10.1016/j.bbadis.2012.11.021 ↗
57. Oury TD. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis10.1016/j.freeradbiomed.2010.04.036 ↗
58. Reconciling the chemistry and biology of reactive oxygen species10.1038/nchembio.85 ↗
59. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy10.1164/rccm.200501-017PP ↗
60. Molecular basis of asbestos-induced lung disease10.1146/annurev-pathol-020712-163942 ↗
61. Redox-based regulation of apoptosis: s-glutathionylation as a regulatory mechanism to control cell death10.1089/ars.2011.4281 ↗
62. Oxidative processing of latent Fas in the endoplasmic reticulum controls the strength of apoptosis10.1128/MCB.00125-12 ↗
63. Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis10.1016/j.freeradbiomed.2009.09.026 ↗
64. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis10.1080/14728222.2018.1541318 ↗
65. TGF-beta: the master regulator of fibrosis10.1038/nrneph.2016.48 ↗
66. Paeoniflorin suppresses TGF-beta mediated epithelial-mesenchymal transition in pulmonary fibrosis through a Smad-dependent pathway10.1038/aps.2016.36 ↗
67. Molecular Mechanisms Underlying Peritoneal EMT and Fibrosis10.1155/2016/3543678 ↗
68. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis10.1016/j.diff.2016.07.001 ↗
69. The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis10.1016/j.diff.2016.05.008 ↗
70. TGF-beta: master regulator of inflammation and fibrosis10.1111/resp.13415 ↗
71. Transforming Growth Factor-beta: master Regulator of the Respiratory System in Health and Disease10.1165/rcmb.2015-0391TR ↗
72. New insights into TGF-beta/Smad signaling in tissue fibrosis10.1016/j.cbi.2018.07.008 ↗
73. TNAP limits TGF-beta-dependent cardiac and skeletal muscle fibrosis by inactivating the SMAD2/3 transcription factors10.1242/jcs.234948 ↗
74. TGF-beta1 signaling and tissue fibrosis